Faes Farma (HAM:FFEA) EBIT: €91.3 Mil (TTM As of Dec. 2025)


HAM:FFEA Faes Farma SA HAM:FFEA
95 GF Score
Price €4.54
GF Value €5.17
! 6 Warning Signs
View Full Analysis

What is Faes Farma EBIT?

Faes Farma HAM:FFEA -0.55% 95 EBIT is €91.3 Mil as of Dec. 2025. GuruFocus rates HAM:FFEA with a GF Score™ of 95/100 and a GF Value™ of €5.17. The stock has 6 warning signs investors should review.

Faes Farma's earnings before interest and taxes (EBIT) for the six months ended in Dec. 2025 was €29.2 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was €91.3 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Faes Farma's annualized ROC % for the quarter that ended in Dec. 2025 was 6.28%. Faes Farma's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 11.51%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Faes Farma's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 5.26%.

Faes Farma  (HAM:FFEA) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Faes Farma's annualized ROC % for the quarter that ended in Dec. 2025 is calculated as:

ROC % (Q: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2025 ) + Invested Capital (Q: Dec. 2025 ))/ count )
=58.996 * ( 1 - 0% )/( (791.636 + 1086.188)/ 2 )
=58.996/938.912
=6.28 %

where

Invested Capital(Q: Jun. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1000.131 - 96.874 - ( 111.621 - max(0, 184.269 - 422.722+111.621))
=791.636

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1341.895 - 125.615 - ( 130.092 - max(0, 184.877 - 482.402+130.092))
=1086.188

Note: The Operating Income data used here is two times the semi-annual (Dec. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

Faes Farma's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2025  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=58.494/( ( (317.796 + max(145.074, 0)) + (353.308 + max(200.499, 0)) )/ 2 )
=58.494/( ( 462.87 + 553.807 )/ 2 )
=58.494/508.3385
=11.51 %

where Working Capital is:

Working Capital(Q: Jun. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(142.596 + 154.721 + 0) - (96.874 + 0 + 55.369)
=145.074

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(152.488 + 182.612 + 3.098) - (125.615 + 0 + 12.084)
=200.499

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Faes Farma's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2025 )
=91.273/1734.232
=5.26 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Faes Farma EBIT Related Terms

Faes Farma EBIT Historical Data

* Premium members only.

The historical data trend for Faes Farma's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Faes Farma EBIT Chart

Faes Farma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 93.18 101.68 103.24 108.01 91.27

Faes Farma Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 31.83 69.12 38.89 62.03 29.25

HAM:FFEA vs ZTS, UTHR, VTRS: EBIT Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Faes Farma's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Faes Farma EV-to-EBIT vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Faes Farma's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Faes Farma's EV-to-EBIT falls into.


HAM:FFEA
95GF Score
Faes Farma SA HAM:FFEA
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Faes Farma EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €91.3 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of €91.3 Mil mean?
Faes Farma (HAM:FFEA) has a EBIT of €91.3 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Faes Farma.
Is Faes Farma's EBIT too high?
Faes Farma's current EBIT is €91.3 Mil. Overall, Faes Farma has a GF Score™ of 95/100, reflecting its overall financial health beyond just this single metric.
How does Faes Farma's EBIT compare to ZTS and UTHR?
Faes Farma's EBIT of €91.3 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Drug Manufacturers company?
A good EBIT depends on the Drug Manufacturers industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Faes Farma. Faes Farma's current EBIT is €91.3 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Faes Farma stock overvalued right now?
Faes Farma (HAM:FFEA) has a current EBIT of €91.3 Mil. The stock's GF Value™ is €5.17, compared to a current price of €4.54 — trading 12.2% below its estimated fair value. The current EBIT is €91.3 Mil. Faes Farma's overall GF Score™ is 95/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Faes Farma (HAM:FFEA), the current EBIT is €91.3 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Faes Farma (HAM:FFEA) Overvalued in 2026?

Based on GuruFocus' analysis, Faes Farma stock appears to be undervalued. The current stock price of €4.54 is trading 12.2% below its estimated GF Value™ of €5.17.

Key valuation signals for HAM:FFEA:

  • EBIT: €91.3 Mil
  • GF Value™: €5.17 vs. price of €4.54 (12.2% below fair value)
  • GF Score™: 95/100 with 6 warning signs

No single metric tells the full story. See the HAM:FFEA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Faes Farma Business Description

Address Avenida Autonomia, 10, Leioa, Vizcaya, ESP, 48940
Faes Farma SA purpose is manufacturing and selling all kinds of chemical and pharmaceutical products, foodstuffs, cosmetics, dietetics and medicinal plants, as well as acquiring, purchasing, disposing of, investing in, holding, using, managing, administering, marketing and leasing corporations, securities and real estate, patents, trademarks and registered brands and equity interests. It is mainly engaged in the manufacture and sale of pharmaceutical products, as well as in the manufacture and sale of animal nutrition and health products. Its segments are Pharmaceutical and healthcare specialities, Animal nutrition and health, and Other segments. It generates majority of revenue from Pharmaceutical and healthcare specialities. It operates mainly in domestic and international markets.
95GF Score

Get the complete analysis for HAM:FFEA

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.54
Price
€5.17
GF Value